Despite the use of effective drug and device therapies, many patients with HFrEF continue to experience worsening symptoms and disease progression. Barostim is a novel device therapy that works with drug therapies to target the neurohormonal pathways responsible for heart failure progression and symptoms. Most importantly, 94% of patients receiving the device had significant improvement in quality of life, exercise capacity or functional status heart failure symptoms.(1)
And a just-out Heart Failure Society of America consensus statement is urging physicians to look to devices earlier in treatment. Two leading heart failure specialists and an HF program leader share their experience, perspective, and outcomes incorporating Barostim into their comprehensive advanced heart failure programs. Plus, we’ll dig into the reimbursement and payment landscape that’s helping programs grow and thrive.
(1) Abraham WT, et al. Symptomatic endpoint responder rates to Barostim Therapy, ESC Abstract 2019
Learn from our experts about:
- Challenges with guideline-directed medical and device therapies (GDMT) in heart failure with reduced ejection fraction (HFrEF)
- How drug therapies and Barostim target the neurohormonal pathways responsible for heart failure progression
- Creating the continuum of heart failure care – and how collaboration improves outcomes
- How to build awareness with referring physicians
- Understanding the value of integrating Barostim into a comprehensive heart failure program
- How facilities are navigating prior authorization and removing barriers to payment
Who should attend:
- Cardiologists
- Advanced Heart Failure
- Cardiology and Heart Failure Administrators
- Billing and Coding Professionals
- Heart Teams
- Cardiovascular Service Line Directors
- Advanced Practice Providers
- Hospital and Health System C-Suite: COOs, CEOs, CFOs
- Vascular and CT Surgeons
Our expert panel:
| 
| 
| 
|